Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the cleantalk-spam-protect domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /wordpress/wp-includes/functions.php on line 6121 Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the divi-booster domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /wordpress/wp-includes/functions.php on line 6121 Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wpmudev domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /wordpress/wp-includes/functions.php on line 6121 Spravato Approved for Treatment-Resistant Depression | DeMarle, Inc.

:Spravato, the esketamine nasal spray, was approved by the FDA for treatment-resistant depression as a monotherapy with no oral antidepressants required.”

By Nicole C. Kear Verified Updated on February 24, 2025

“Spravato, the esketamine nasal spray approved in 2019 for use alongside oral antidepressants for treatment-resistant depression, has been approved by the U.S. Food and Drug Administration (FDA) as a standalone monotherapy with no oral medication required.

Esketamine is a form of the dissociative agent ketamine, commonly used as an anesthetic; it works by targeting the neurotransmitter glutamate. According to a randomized, double-blind, placebo-controlled study, 22.5% of patients who took Spravato alone for four months achieved remission from depression (as measured by MADRS) compared with 7.6% of patients taking placebo.1